Hyperuricemia can be divided into primary hyperuricemia (usually due to an increased production of uric acid from purine or due to the kidneys malfunctioning) and secondary hyperuricemia. The latter can be caused by a multitude of factors and diseases, notably certain cancers and chemotherapy agents that markedly increase the turnover rate of cell death.

Clinically relevant HUA models are critical for the development of better treatments, so having access to these models, as well as working with a CRO with unrivaled knowledge and skills in preclinical pharmacology, is pivotal for the outcome of your candidates. Contact us at PharmaLegacy so that we discuss the next step in your preclinical HUA studies.